Edgewise Therapeutics (EWTX) provided updates on its clinical programs and highlighted major milestones for 2026. 2026 priorities include: Sevasemten: complete the GRAND CANYON global pivotal cohort and announce top-line results in individuals with Becker in Q4, prepare for submission of an NDA with the FDA for sevasemten in Becker in 1H27; finalize the design and plan for a Phase 3 trial in individuals with Duchenne in 2H26. For EDG-7500: report data in individuals with obstructive and nonobstructive HCM in 1H26; initiate Phase 3 trial in obstructive and nonobstructive HCM in 2H26. For EDG-15400: report Phase 1 data of EDG-15400 in healthy adults in 1H26; initiate Phase 2 trial in participants with heart failure with preserved ejection fraction with results anticipated in 1H27.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise reports inducement grants as permitted by Nasdaq listing rules
- Edgewise Therapeutics: Advancing EDG-7500 in Hypertrophic Cardiomyopathy Underpins Buy Rating and Future Value Catalysts
- Edgewise Therapeutics rises 20.3%
- Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating
- H.C. Wainwright says Edgewise data reinforces EDG-7500 potential differentiation